Endothelium

Last updated
Endothelium
Microscopic anatomy of an artery en.svg
Diagram showing the location of endothelial cells
Microvessel.jpg
Transmission electron micrograph of a microvessel showing endothelial cells, which encircle an erythrocyte (E), forming the innermost layer of the vessel, the tunica intima.
Details
System Circulatory system
LocationLining of the inner surface of blood vessels and lymphatic vessels
Identifiers
MeSH D004727
TH H2.00.02.0.02003
FMA 63916
Anatomical terms of microanatomy

The endothelium (pl.: endothelia) is a single layer of squamous endothelial cells that line the interior surface of blood vessels and lymphatic vessels. [1] The endothelium forms an interface between circulating blood or lymph in the lumen and the rest of the vessel wall.

Contents

Endothelial cells in direct contact with blood are called vascular endothelial cells whereas those in direct contact with lymph are known as lymphatic endothelial cells. Vascular endothelial cells line the entire circulatory system, from the heart to the smallest capillaries.

These cells have unique functions that include fluid filtration, such as in the glomerulus of the kidney, blood vessel tone, hemostasis, neutrophil recruitment, and hormone trafficking. Endothelium of the interior surfaces of the heart chambers is called endocardium. An impaired function can lead to serious health issues throughout the body.

Structure

The endothelium is a thin layer of single flat (squamous) cells that line the interior surface of blood vessels and lymphatic vessels. [1]

Endothelium is of mesodermal origin. Both blood and lymphatic capillaries are composed of a single layer of endothelial cells called a monolayer. In straight sections of a blood vessel, vascular endothelial cells typically align and elongate in the direction of fluid flow. [2] [3]

Terminology

The foundational model of anatomy, an index of terms used to describe anatomical structures, makes a distinction between endothelial cells and epithelial cells on the basis of which tissues they develop from, and states that the presence of vimentin rather than keratin filaments separates these from epithelial cells. [4] Many considered the endothelium a specialized epithelial tissue. [5]

Function

Endothelium lines the inner wall of vessels, shown here. 2104 Three Major Capillary Types.jpg
Endothelium lines the inner wall of vessels, shown here.
Microscopic view showing endothelium (at top) inside the heart. Endocardium and subendocardium histology.png
Microscopic view showing endothelium (at top) inside the heart.

The endothelium forms an interface between circulating blood or lymph in the lumen and the rest of the vessel wall. This forms a barrier between vessels and tissues and control the flow of substances and fluid into and out of a tissue. This controls the passage of materials and the transit of white blood cells into and out of the bloodstream. Excessive or prolonged increases in permeability of the endothelium, as in cases of chronic inflammation, may lead to tissue swelling (edema). Altered barrier function is also implicated in cancer extravasation. [6]

Endothelial cells are involved in many other aspects of vessel function, including:

Blood vessel formation

The endothelium is involved in the formation of new blood vessels, called angiogenesis. [11] Angiogenesis is a crucial process for development of organs in the embryo and fetus, [12] as well as repair of damaged areas. [13] The process is triggered by decreased tissue oxygen (hypoxia) or insufficient oxygen tension leading to the new development of blood vessels lined with endothelial cells. Angiogenesis is regulated by signals that promote and decrease the process. These pro- and antiangiogenic signals including integrins, chemokines, angiopoietins, oxygen sensing agents, junctional molecules and endogenous inhibitors. [12] Angiopoietin-2 works with VEGF to facilitate cell proliferation and migration of endothelial cells.

The general outline of angiogenesis is

Host immune response

Endothelial cells express a variety of immune genes in an organ-specific manner. [14] These genes include critical immune mediators and proteins that facilitate cellular communication with hematopoietic immune cells. [15] Endothelial cells encode important features of the structural cell immune response in the epigenome and can therefore respond swiftly to immunological challenges. The contribution to host immunity by non-hematopoietic cells, such as endothelium, is called “structural immunity”. [16]

Clinical significance

Endothelial dysfunction, or the loss of proper endothelial function, is a hallmark for vascular diseases, and is often regarded as a key early event in the development of atherosclerosis. [17] Impaired endothelial function, causing hypertension and thrombosis, is often seen in patients with coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, as well as in smokers. Endothelial dysfunction has also been shown to be predictive of future adverse cardiovascular events including stroke, heart disease, and is also present in inflammatory disease such as rheumatoid arthritis, diabetes, and systemic lupus erythematosus. [18] [19]

Endothelial dysfunction is a result of changes in endothelial function. [20] [21] After fat (lipid) accumulation and when stimulated by inflammation, endothelial cells become activated, which is characterized by the expression of molecules such as E-selectin, VCAM-1 and ICAM-1, which stimulate the adhesion of immune cells. [22] Additionally, transcription factors, which are substances which act to increase the production of proteins within cells, become activated; specifically AP-1 and NF-κB, leading to increased expression of cytokines such as IL-1, TNFα and IFNγ, which promotes inflammation. [23] [24] This state of endothelial cells promotes accumulation of lipids and lipoproteins in the intima, leading to atherosclerosis, and the subsequent recruitment of white blood cells and platelets, as well as proliferation of smooth muscle cells, leading to the formation of a fatty streak. The lesions formed in the intima, and persistent inflammation lead to desquamation of endothelium, which disrupts the endothelial barrier, leading to injury and consequent dysfunction. [25] In contrast, inflammatory stimuli also activate NF-κB-induced expression of the deubiquitinase A20 (TNFAIP3), which has been shown to intrinsically repair the endothelial barrier. [26]

One of the main mechanisms of endothelial dysfunction is the diminishing of nitric oxide, often due to high levels of asymmetric dimethylarginine, which interfere with the normal L-arginine-stimulated nitric oxide synthesis and so leads to hypertension. The most prevailing mechanism of endothelial dysfunction is an increase in reactive oxygen species, which can impair nitric oxide production and activity via several mechanisms. [27] The signalling protein ERK5 is essential for maintaining normal endothelial cell function. [28] A further consequence of damage to the endothelium is the release of pathological quantities of von Willebrand factor, which promote platelet aggregation and adhesion to the subendothelium, and thus the formation of potentially fatal thrombi.

Angiosarcoma is cancer of the endothelium and is rare with only 300 cases per year in the US. [29] However it generally has poor prognosis with a five-year survival rate of 35%. [30]

Research

Endothelium in cancer

It has been recognised that endothelial cells building tumour vasculature have distinct morphological characteristics, different origin compared to physiological endothelium, and distinct molecular signature, which gives an opportunity for implementation of new biomarkers of tumour angiogenesis and could provide new anti-angiogenic druggable targets. [31]

Endothelium in diet

A healthy diet abundant in fruits and vegetables has a beneficial impact on endothelial function, whilst a diet high in red and processed meats, fried foods, refined grains and processed sugar increases adhesion endothelial cells and atherogenic promoters. [32] High-fat diets adversely affect the endothelial function. [33]

A Mediterranean diet has been found to improve endothelial function in adults which can reduce risk of cardiovascular disease. [34] [35] Walnut consumption improves endothelial function. [36] [37]

Endothelium in Covid-19

In April 2020, the presence of viral elements in endothelial cells of 3 patients who had died of COVID-19 was reported for the first time. The researchers from the University of Zurich and Harvard Medical School considered these findings to be a sign of a general endotheliitis in different organs, an inflammatory response of the endothelium to the infection that can lead or at least contribute to multi-organ failure in Covid-19 patients with comorbidities such as diabetes mellitus, hypertension and cardiovascular disease. [38] [39]

History

In 1865, the Swiss anatomist Wilhelm His first coin the term “endothelium”. [40] In 1958, A. S. Todd of the University of St Andrews demonstrated that endothelium in human blood vessels have fibrinolytic activity. [41] [42]

See also

List of distinct cell types in the adult human body

Related Research Articles

<span class="mw-page-title-main">Angiogenesis</span> Blood vessel formation, when new vessels emerge from existing vessels

Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels, formed in the earlier stage of vasculogenesis. Angiogenesis continues the growth of the vasculature mainly by processes of sprouting and splitting, but processes such as coalescent angiogenesis, vessel elongation and vessel cooption also play a role. Vasculogenesis is the embryonic formation of endothelial cells from mesoderm cell precursors, and from neovascularization, although discussions are not always precise. The first vessels in the developing embryo form through vasculogenesis, after which angiogenesis is responsible for most, if not all, blood vessel growth during development and in disease.

<span class="mw-page-title-main">Inflammation</span> Physical effects resulting from activation of the immune system

Inflammation is part of the biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. The five cardinal signs are heat, pain, redness, swelling, and loss of function.

<span class="mw-page-title-main">Atherosclerosis</span> Inflammatory disease involving buildup of lesions in the walls of arteries

Atherosclerosis is a pattern of the disease arteriosclerosis, characterized by development of abnormalities called lesions in walls of arteries. This is a chronic inflammatory disease involving many different cell types, and driven by elevated levels of cholesterol in the blood. These lesions may lead to narrowing of the arterial walls due to buildup of atheromatous plaques. At onset there are usually no symptoms, but if they develop, symptoms generally begin around middle age. In severe cases, it can result in coronary artery disease, stroke, peripheral artery disease, or kidney disorders, depending on which body part(s) the affected arteries are located in the body.

<span class="mw-page-title-main">Microangiopathy</span> Medical condition

Microangiopathy is a disease of the microvessels, small blood vessels in the microcirculation. It can be contrasted to macroangiopathies such as atherosclerosis, where large and medium-sized arteries are primarily affected.

<span class="mw-page-title-main">Vasodilation</span> Widening of blood vessels

Vasodilation, also known as vasorelaxation, is the widening of blood vessels. It results from relaxation of smooth muscle cells within the vessel walls, in particular in the large veins, large arteries, and smaller arterioles. Blood vessel walls are composed of endothelial tissue and a basal membrane lining the lumen of the vessel, concentric smooth muscle layers on top of endothelial tissue, and an adventitia over the smooth muscle layers. Relaxation of the smooth muscle layer allows the blood vessel to dilate, as it is held in a semi-constricted state by sympathetic nervous system activity. Vasodilation is the opposite of vasoconstriction, which is the narrowing of blood vessels.

<span class="mw-page-title-main">Endothelial dysfunction</span> Impaired function of the inner lining of blood/lymph vessels

In vascular diseases, endothelial dysfunction is a systemic pathological state of the endothelium. The main cause of endothelial dysfunction is impaired bioavailability of nitric oxide.

<span class="mw-page-title-main">Glycocalyx</span> Viscous, carbohydrate rich layer at the outermost periphery of a cell.

The glycocalyx, also known as the pericellular matrix and sometime cell coat, is a glycoprotein and glycolipid covering which surrounds the cell membranes of bacteria, epithelial cells, and other cells. It was described in a review article in 1970.

<span class="mw-page-title-main">Plasminogen activator inhibitor-1</span> Human protein

Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor is a protein that in humans is encoded by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis.

<span class="mw-page-title-main">Endothelin</span>

Endothelins are peptides with receptors and effects in many body organs. Endothelin constricts blood vessels and raises blood pressure. The endothelins are normally kept in balance by other mechanisms, but when overexpressed, they contribute to high blood pressure (hypertension), heart disease, and potentially other diseases.

<span class="mw-page-title-main">Tissue factor</span> Protein involved in coagulation

Tissue factor, also called platelet tissue factor or Coagulation factor III, is a protein present in subendothelial tissue and leukocytes which plays a major role in coagulation and, in humans, is encoded by F3 gene. Its role in the blood clotting is the initiation of thrombin formation from the zymogen prothrombin. Thromboplastin defines the cascade that leads to the activation of factor X—the tissue factor pathway. In doing so, it has replaced the previously named extrinsic pathway in order to eliminate ambiguity.

The epoxyeicosatrienoic acids or EETs are signaling molecules formed within various types of cells by the metabolism of arachidonic acid by a specific subset of cytochrome P450 enzymes termed cytochrome P450 epoxygenases. These nonclassic eicosanoids are generally short-lived, being rapidly converted from epoxides to less active or inactive dihydroxy-eicosatrienoic acids (diHETrEs) by a widely distributed cellular enzyme, soluble epoxide hydrolase (sEH), also termed epoxide hydrolase 2. The EETs consequently function as transiently acting, short-range hormones; that is, they work locally to regulate the function of the cells that produce them or of nearby cells. The EETs have been most studied in animal models where they show the ability to lower blood pressure possibly by a) stimulating arterial vasorelaxation and b) inhibiting the kidney's retention of salts and water to decrease intravascular blood volume. In these models, EETs prevent arterial occlusive diseases such as heart attacks and brain strokes not only by their anti-hypertension action but possibly also by their anti-inflammatory effects on blood vessels, their inhibition of platelet activation and thereby blood clotting, and/or their promotion of pro-fibrinolytic removal of blood clots. With respect to their effects on the heart, the EETs are often termed cardio-protective. Beyond these cardiovascular actions that may prevent various cardiovascular diseases, studies have implicated the EETs in the pathological growth of certain types of cancer and in the physiological and possibly pathological perception of neuropathic pain. While studies to date imply that the EETs, EET-forming epoxygenases, and EET-inactivating sEH can be manipulated to control a wide range of human diseases, clinical studies have yet to prove this. Determination of the role of the EETS in human diseases is made particularly difficult because of the large number of EET-forming epoxygenases, large number of epoxygenase substrates other than arachidonic acid, and the large number of activities, some of which may be pathological or injurious, that the EETs possess.

<span class="mw-page-title-main">Endothelial stem cell</span> Stem cell in bone marrow that gives rise to endothelial cells

Endothelial stem cells (ESCs) are one of three types of stem cells found in bone marrow. They are multipotent, which describes the ability to give rise to many cell types, whereas a pluripotent stem cell can give rise to all types. ESCs have the characteristic properties of a stem cell: self-renewal and differentiation. These parent stem cells, ESCs, give rise to progenitor cells, which are intermediate stem cells that lose potency. Progenitor stem cells are committed to differentiating along a particular cell developmental pathway. ESCs will eventually produce endothelial cells (ECs), which create the thin-walled endothelium that lines the inner surface of blood vessels and lymphatic vessels. The blood vessels include arteries and veins. Endothelial cells can be found throughout the whole vascular system and they also play a vital role in the movement of white blood cells

<span class="mw-page-title-main">Vascular disease</span> Medical condition

Vascular disease is a class of diseases of the vessels of the circulatory system in the body, including blood vessels – the arteries and veins, and the lymphatic vessels. Vascular disease is a subgroup of cardiovascular disease. Disorders in this vast network of blood and lymph vessels can cause a range of health problems that can sometimes become severe, and fatal. Coronary heart disease for example, is the leading cause of death for men and women in the United States.

<span class="mw-page-title-main">Angiopoietin</span> Protein family

Angiopoietin is part of a family of vascular growth factors that play a role in embryonic and postnatal angiogenesis. Angiopoietin signaling most directly corresponds with angiogenesis, the process by which new arteries and veins form from preexisting blood vessels. Angiogenesis proceeds through sprouting, endothelial cell migration, proliferation, and vessel destabilization and stabilization. They are responsible for assembling and disassembling the endothelial lining of blood vessels. Angiopoietin cytokines are involved with controlling microvascular permeability, vasodilation, and vasoconstriction by signaling smooth muscle cells surrounding vessels. There are now four identified angiopoietins: ANGPT1, ANGPT2, ANGPTL3, ANGPT4.

<span class="mw-page-title-main">Thromboxane receptor</span> Mammalian protein found in Homo sapiens

The thromboxane receptor (TP) also known as the prostanoid TP receptor is a protein that in humans is encoded by the TBXA2R gene, The thromboxane receptor is one among the five classes of prostanoid receptors and was the first eicosanoid receptor cloned. The TP receptor derives its name from its preferred endogenous ligand thromboxane A2.

<span class="mw-page-title-main">Microvesicle</span> Type of extracellular vesicle

Microvesicles are a type of extracellular vesicle (EV) that are released from the cell membrane. In multicellular organisms, microvesicles and other EVs are found both in tissues and in many types of body fluids. Delimited by a phospholipid bilayer, microvesicles can be as small as the smallest EVs or as large as 1000 nm. They are considered to be larger, on average, than intracellularly-generated EVs known as exosomes. Microvesicles play a role in intercellular communication and can transport molecules such as mRNA, miRNA, and proteins between cells.

<span class="mw-page-title-main">Endothelial NOS</span> Protein and coding gene in humans

Endothelial NOS (eNOS), also known as nitric oxide synthase 3 (NOS3) or constitutive NOS (cNOS), is an enzyme that in humans is encoded by the NOS3 gene located in the 7q35-7q36 region of chromosome 7. This enzyme is one of three isoforms that synthesize nitric oxide (NO), a small gaseous and lipophilic molecule that participates in several biological processes. The other isoforms include neuronal nitric oxide synthase (nNOS), which is constitutively expressed in specific neurons of the brain and inducible nitric oxide synthase (iNOS), whose expression is typically induced in inflammatory diseases. eNOS is primarily responsible for the generation of NO in the vascular endothelium, a monolayer of flat cells lining the interior surface of blood vessels, at the interface between circulating blood in the lumen and the remainder of the vessel wall. NO produced by eNOS in the vascular endothelium plays crucial roles in regulating vascular tone, cellular proliferation, leukocyte adhesion, and platelet aggregation. Therefore, a functional eNOS is essential for a healthy cardiovascular system.

<span class="mw-page-title-main">20-Hydroxyeicosatetraenoic acid</span> Chemical compound

20-Hydroxyeicosatetraenoic acid, also known as 20-HETE or 20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid, is an eicosanoid metabolite of arachidonic acid that has a wide range of effects on the vascular system including the regulation of vascular tone, blood flow to specific organs, sodium and fluid transport in the kidney, and vascular pathway remodeling. These vascular and kidney effects of 20-HETE have been shown to be responsible for regulating blood pressure and blood flow to specific organs in rodents; genetic and preclinical studies suggest that 20-HETE may similarly regulate blood pressure and contribute to the development of stroke and heart attacks. Additionally the loss of its production appears to be one cause of the human neurological disease, Hereditary spastic paraplegia. Preclinical studies also suggest that the overproduction of 20-HETE may contribute to the progression of certain human cancers, particularly those of the breast.

<span class="mw-page-title-main">Hypertension and the brain</span>

Hypertension is a condition characterized by an elevated blood pressure in which the long term consequences include cardiovascular disease, kidney disease, adrenal gland tumors, vision impairment, memory loss, metabolic syndrome, stroke and dementia. It affects nearly 1 in 2 Americans and remains as a contributing cause of death in the United States. There are many genetic and environmental factors involved with the development of hypertension including genetics, diet, and stress.

<span class="mw-page-title-main">Endothelial cell anergy</span> Defense mechanism of tumors against immunity

Endothelial cell anergy is a condition during the process of angiogenesis, where endothelial cells, the cells that line the inside of blood vessels, can no longer respond to inflammatory cytokines. These cytokines are necessary to induce the expression of cell adhesion molecules to allow leukocyte infiltration from the blood into the tissue at places of inflammation, such as a tumor. This condition, which protects the tumor from the immune system, is the result of exposure to angiogenic growth factors.

References

  1. 1 2 "Endothelium" at Dorland's Medical Dictionary
  2. Eskin SG, Ives CL, McIntire LV, Navarro LT (July 1984). "Response of cultured endothelial cells to steady flow". Microvascular Research. 28 (1): 87–94. doi:10.1016/0026-2862(84)90031-1. PMID   6748961.
  3. Langille BL, Adamson SL (April 1981). "Relationship between blood flow direction and endothelial cell orientation at arterial branch sites in rabbits and mice". Circulation Research. 48 (4): 481–488. doi: 10.1161/01.RES.48.4.481 . PMID   7460219.
  4. "Endothelial cell". BioPortal. Stanford University. Archived from the original on 2013-10-02. Retrieved 2013-09-28.
  5. Kovacic JC, Mercader N, Torres M, Boehm M, Fuster V (April 2012). "Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease". Circulation. 125 (14): 1795–1808. doi:10.1161/circulationaha.111.040352. PMC   3333843 . PMID   22492947.
  6. Escribano J, Chen MB, Moeendarbary E, Cao X, Shenoy V, Garcia-Aznar JM, et al. (May 2019). "Balance of mechanical forces drives endothelial gap formation and may facilitate cancer and immune-cell extravasation". PLOS Computational Biology. 15 (5): e1006395. arXiv: 1811.09326 . Bibcode:2019PLSCB..15E6395E. doi: 10.1371/journal.pcbi.1006395 . PMC   6497229 . PMID   31048903.
  7. Félétou, Michel (2011), "Multiple Functions of the Endothelial Cells", The Endothelium: Part 1: Multiple Functions of the Endothelial Cells—Focus on Endothelium-Derived Vasoactive Mediators, Morgan & Claypool Life Sciences, retrieved 2024-05-20
  8. Weitz, Jeffrey I. (2003-04-01). "Heparan sulfate: Antithrombotic or not?". Journal of Clinical Investigation. 111 (7): 952–954. doi:10.1172/JCI200318234. ISSN   0021-9738. PMC   152594 . PMID   12671043.
  9. Li X, Fang P, Li Y, Kuo YM, Andrews AJ, Nanayakkara G, et al. (June 2016). "Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation". Arteriosclerosis, Thrombosis, and Vascular Biology. 36 (6): 1090–1100. doi:10.1161/ATVBAHA.115.306964. PMC   4882253 . PMID   27127201.
  10. Vestweber D (November 2015). "How leukocytes cross the vascular endothelium". Nature Reviews. Immunology. 15 (11): 692–704. doi:10.1038/nri3908. PMID   26471775. S2CID   29703333.
  11. Griffioen, A. W.; Molema, G. (2000). "Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation". Pharmacological Reviews. 52 (2): 237–268. PMID   10835101.
  12. 1 2 Bouïs D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA (February 2006). "A review on pro- and anti-angiogenic factors as targets of clinical intervention". Pharmacological Research. 53 (2): 89–103. doi:10.1016/j.phrs.2005.10.006. PMID   16321545.
  13. Dudley, A. C.; Griffioen, A. W. (2023). "Pathological angiogenesis: Mechanisms and therapeutic strategies". Angiogenesis. 26 (3): 313–347. doi:10.1007/s10456-023-09876-7. PMC   10105163 . PMID   37060495.
  14. Krausgruber T, Fortelny N, Fife-Gernedl V, Senekowitsch M, Schuster LC, Lercher A, et al. (July 2020). "Structural cells are key regulators of organ-specific immune responses". Nature. 583 (7815): 296–302. Bibcode:2020Natur.583..296K. doi: 10.1038/s41586-020-2424-4 . PMC   7610345 . PMID   32612232. S2CID   220295181.
  15. Armingol E, Officer A, Harismendy O, Lewis NE (February 2021). "Deciphering cell-cell interactions and communication from gene expression". Nature Reviews. Genetics. 22 (2): 71–88. doi:10.1038/s41576-020-00292-x. PMC   7649713 . PMID   33168968.
  16. Minton K (September 2020). "A gene atlas of 'structural immunity'". Nature Reviews. Immunology. 20 (9): 518–519. doi: 10.1038/s41577-020-0398-y . PMID   32661408. S2CID   220491226.
  17. Botts SR, Fish JE, Howe KL (December 2021). "Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment". Frontiers in Pharmacology. 12: 787541. doi: 10.3389/fphar.2021.787541 . PMC   8727904 . PMID   35002720.
  18. Tsukahara T, Tsukahara R, Haniu H, Matsuda Y, Murakami-Murofushi K (September 2015). "Cyclic phosphatidic acid inhibits the secretion of vascular endothelial growth factor from diabetic human coronary artery endothelial cells through peroxisome proliferator-activated receptor gamma". Molecular and Cellular Endocrinology. 412: 320–329. doi:10.1016/j.mce.2015.05.021. hdl: 10069/35888 . PMID   26007326. S2CID   10454566.
  19. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I (2013-11-09). "The vascular endothelium and human diseases". International Journal of Biological Sciences. 9 (10): 1057–1069. doi:10.7150/ijbs.7502. PMC   3831119 . PMID   24250251.
  20. Iantorno M, Campia U, Di Daniele N, Nistico S, Forleo GB, Cardillo C, Tesauro M (April 2014). "Obesity, inflammation and endothelial dysfunction". Journal of Biological Regulators and Homeostatic Agents. 28 (2): 169–176. PMID   25001649.
  21. Reriani MK, Lerman LO, Lerman A (June 2010). "Endothelial function as a functional expression of cardiovascular risk factors". Biomarkers in Medicine. 4 (3): 351–360. doi:10.2217/bmm.10.61. PMC   2911781 . PMID   20550469.
  22. Lopez-Garcia E, Hu FB (August 2004). "Nutrition and the endothelium". Current Diabetes Reports. 4 (4): 253–259. doi:10.1007/s11892-004-0076-7. PMID   15265466. S2CID   24878288.
  23. Blake GJ, Ridker PM (October 2002). "Inflammatory bio-markers and cardiovascular risk prediction". Journal of Internal Medicine. 252 (4): 283–294. doi: 10.1046/j.1365-2796.2002.01019.x . PMID   12366601. S2CID   26400610.
  24. Mizuno Y, Jacob RF, Mason RP (2011). "Inflammation and the development of atherosclerosis". Journal of Atherosclerosis and Thrombosis. 18 (5): 351–358. doi: 10.5551/jat.7591 . PMID   21427505.
  25. Mäyränpää MI, Heikkilä HM, Lindstedt KA, Walls AF, Kovanen PT (November 2006). "Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion". Coronary Artery Disease. 17 (7): 611–621. doi:10.1097/01.mca.0000224420.67304.4d. PMID   17047445. S2CID   1884596.
  26. Soni D, Wang DM, Regmi SC, Mittal M, Vogel SM, Schlüter D, Tiruppathi C (May 2018). "Deubiquitinase function of A20 maintains and repairs endothelial barrier after lung vascular injury". Cell Death Discovery. 4 (60): 60. doi:10.1038/s41420-018-0056-3. PMC   5955943 . PMID   29796309.
  27. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. (January 2005). "Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension". Journal of Hypertension. 23 (1): 7–17. doi:10.1097/00004872-200501000-00004. PMID   15643116.
  28. Roberts OL, Holmes K, Müller J, Cross DA, Cross MJ (December 2009). "ERK5 and the regulation of endothelial cell function". Biochemical Society Transactions. 37 (Pt 6): 1254–1259. doi:10.1042/BST0371254. PMID   19909257.
  29. "Angiosarcoma - National Cancer Institute". www.cancer.gov. 2019-02-27. Retrieved 2021-08-10.
  30. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ (October 2010). "Angiosarcoma". The Lancet. Oncology. 11 (10): 983–991. doi:10.1016/S1470-2045(10)70023-1. PMID   20537949.
    • Milosevic V, Edelmann RJ, Fosse JH, Östman A, Akslen LA (2022). "Molecular Phenotypes of Endothelial Cells in Malignant Tumors.". In Akslen LA, Watnick RS (eds.). Biomarkers of the Tumor Microenvironment. Cham: Springer. pp. 31–52. doi:10.1007/978-3-030-98950-7_3. ISBN   978-3-030-98949-1.
  31. Defagó MD, Elorriaga N, Irazola VE, Rubinstein AL (December 2014). "Influence of food patterns on endothelial biomarkers: a systematic review". Journal of Clinical Hypertension. 16 (12): 907–913. doi:10.1111/jch.12431. PMC   4270900 . PMID   25376124.
  32. Fewkes JJ, Kellow NJ, Cowan SF, Williamson G, Dordevic AL (September 2022). "A single, high-fat meal adversely affects postprandial endothelial function: a systematic review and meta-analysis". The American Journal of Clinical Nutrition. 116 (3): 699–729. doi:10.1093/ajcn/nqac153. PMC   9437993 . PMID   35665799.
  33. Shannon OM, Mendes I, Köchl C, Mazidi M, Ashor AW, Rubele S, et al. (May 2020). "Mediterranean Diet Increases Endothelial Function in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". The Journal of Nutrition. 150 (5): 1151–1159. doi: 10.1093/jn/nxaa002 . PMID   32027740.
  34. Fatima K, Rashid AM, Memon UA, Fatima SS, Javaid SS, Shahid O, et al. (February 2022). "Mediterranean Diet and its Effect on Endothelial Function: A Meta-analysis and Systematic Review". Irish Journal of Medical Science. 192 (1): 105–113. doi: 10.1007/s11845-022-02944-9 . PMC   9892125 . PMID   35192097. S2CID   247013758.
  35. Mohammadi-Sartang M, Bellissimo N, Totosy de Zepetnek JO, Bazyar H, Mahmoodi M, Mazloom Z (December 2018). "Effects of walnuts consumption on vascular endothelial function in humans: A systematic review and meta-analysis of randomized controlled trials". Clinical Nutrition ESPEN. 28: 52–58. doi:10.1016/j.clnesp.2018.07.009. PMID   30390893. S2CID   53221430.
  36. Xiao Y, Huang W, Peng C, Zhang J, Wong C, Kim JH, et al. (June 2018). "Effect of nut consumption on vascular endothelial function: A systematic review and meta-analysis of randomized controlled trials". Clinical Nutrition. 37 (3): 831–839. doi:10.1016/j.clnu.2017.04.011. PMID   28457654. S2CID   13930609.
  37. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. (May 2020). "Endothelial cell infection and endotheliitis in COVID-19". Lancet. 395 (10234): 1417–1418. doi:10.1016/S0140-6736(20)30937-5. PMC   7172722 . PMID   32325026.
  38. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G (May 2020). "Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence". Journal of Clinical Medicine. 9 (5): 1417. doi: 10.3390/jcm9051417 . PMC   7290769 . PMID   32403217.
  39. Félétou, Michel (2011), "Introduction", The Endothelium: Part 1: Multiple Functions of the Endothelial Cells—Focus on Endothelium-Derived Vasoactive Mediators, Morgan & Claypool Life Sciences, retrieved 2024-05-20
  40. Todd AS (February 1958). "Fibrinolysis autographs". Nature. 181 (4607): 495–496. Bibcode:1958Natur.181..495T. doi:10.1038/181495b0. eISSN   1476-4687. PMID   13517190. S2CID   4219257.
  41. Todd AS (September 1964). "Localization of Fibrinolytic Activity in Tissues". British Medical Bulletin. 20 (3): 210–212. doi:10.1093/oxfordjournals.bmb.a070333. eISSN   1471-8391. PMID   14209761.